Multiple Myeloma and Cellular Therapies

Dear Colleagues,

Although the introduction of innovative drug therapies has led to the improvement of median overall survival from 3 to 6–7 years in the last 2 decades, multiple myeloma (MM) remains an incurable disease. The most recent clinical research includes monoclonal antibodies and cellular therapies. In this Topical Collection, we will focus on the following items: (1) high dose therapy followed by the reinfusion of autologous stem cells is the “gold standard” for newly diagnosed MM; however, the eligibility of elderly patients, new conditioning regimens, and novel drugs before and after autologous transplant are areas of current active investigation; (2) allogeneic stem cell transplantation can be reserved to fit patients with very high-risk MM, but transplant indications and strategies to reduce transplant-related mortality and the relapse risk are controversial; (3) chimeric antigen receptor (CAR) T cell therapy directed to B cell maturation antigen (BCMA) is the most innovative treatment for relapsed and refractory disease with several phase II and III studies recruiting worldwide, and with ongoing basic research aiming to improve T cell engineering and persistence.

We look forward to your contributions.

Dr. Francesca Patriarca
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.